Clinical stage biopharmaceutical company Cellectar Biosciences (CLRB), said a patient with a rare type of cancer that begins in the white blood cells, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses, in a mid-stage cancer study. CLRB is currently trading up 1365.95% at $10.98.
Key takeaways from the company's Press Release
* Prior to study enrollment, this 67-year-old female patient was diagnosed with Waldenstrom macroglobulinemia (a rare type of cancer that begins in the white blood cells) had received two lines of multi-drug therapy with the most recent treatment achieving a best response of disease progression
*As part of Cellectar's Phase 2 study in hematologic cancers, the patient received a single 25mCi/m2 dose of the company's investigational drug CLR 131 over a 30-minute infusion period. On day 52 post infusion, a CT scan showed a >50% reduction in tumor volume and was classified as a partial response.
*Based on this initial response and additional clinical factors, the treating physician administered a second dose of CLR 131 on day 123. A CT scan taken 64 days after the second dose, showed a 94% overall reduction in tumor burden and complete resolution in four of five targeted tumor masses. The total targeted tumor mass shrank from approximately 4700mm2 prior to the first CLR 131 infusion to approximately 500mm2 at last reading.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.